Total
0
Shares
Actinogen Medical (ASX:ACW) granted ethics committee approval for Alzheimers study
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Actinogen Medical (ACW) is clear to enrol first patients into its Alzheimer’s Disease treatment clinical trial after receiving ethics committee approval
  • ACW is now able to commence the first stage of its two-part XanaMIA studies, which will study improvements in cognitive ability in patients and volunteers with the first clinical stage of Alzheimers
  • The first stage of the study — XanaMIA Part A — will include 100 healthy patients to confirm the maximum effective dose of its proposed treatment candidate, Xanamem
  • From there, XanaMIA Part B will assess the efficacy of Xanamem using the minimum effective dose conducted in a cohort of patients
  • Actinogen Medical shares are up 11.9 per cent following the announcement and trading at 11.8 cents

Actinogen Medical (ACW) is clear to enrol first patients into its Alzheimer’s Disease treatment clinical trial after receiving ethics committee approval.

The clinical-stage biotechnology company received approval from the Bellberry Human Research Ethics Committee meaning it can commence the first stage of its XanaMIA study.

Broadly, the two-part study is designed to study improvements in cognitive ability in older volunteers, and patients with Mild Cognitive Impairment (MCI), the first clinical stage of Alzheimers, with the first patients set to enrol in July.

The first stage of the study — XanaMIA Part A — will include 100 healthy patients and be conducted across four clinics in Australia in a dose-ranging study of five milligram and 10 milligram Xanamem doses, to confirm the minimum effective dose.

According to ACW, Xanamem was developed in response to evidence of a strong association between chronically raised cortisol levels in the blood and in the brain and the development of cognitive impairment associated with a number of conditions and Alzheimer’s disease.

From there, XanaMIA Part B will assess the efficacy of Xanamem using the minimum effective dose conducted in a cohort of patients with Mild Cognitive Impairment due to biomarker positive, early-stage Alzheimer’s Disease.

Actinogen Medical shares are up 11.9 per cent following the announcement and trading at 11.8 cents at 11:21 am AEST.

ACW by the numbers
More From The Market Herald
Creso Pharma (ASX:CPH) - Creso Pharma - The Market Herald

" Creso Pharma (ASX:CPH) completes US dual listing

Creso Pharma (CPH) is officially dual listed, after completing its listing on the US OTCQB stock exchange.
The Market Herald Video

" US regulator approves expanded use of Avita Medical’s (ASX:AVH) RECELL System

The US regulator has approved the expanded use of Avita Medical’s (AVH) RECELL system in combination with meshed autographs to treat burns patients.
Advanced Human Imaging (ASX:AHI) - CEO, Vlado Bosanac - The Market Herald

" Advanced Human Imaging (ASX:AHI) signs term sheet with Cubert

Advanced Human Imaging (AHI) has signed a binding term sheet with Toronto-based digital health provider Cubert Inc.
Microequities Asset Management (ASX:MAM) posts 140pc boost to half-yearly profit

" Patrys (ASX:PAB) receives $600k R&D tax incentive refund

Patrys (PAB), through its wholly owned Nucleus Therapeutics subsidiary, has received a research and development (R&D) tax incentive refund of $626,780 for the